188057-26-3 Usage
Description
6-Chloro-2-iodo-3-hydroxypyridine is an organic compound with the molecular formula C5H3ClINO. It is a derivative of pyridine, a heterocyclic compound with a nitrogen atom in the ring structure. This specific compound features a chlorine atom at the 6th position, an iodine atom at the 2nd position, and a hydroxyl group at the 3rd position. Its chemical structure endows it with unique properties that make it suitable for various applications across different industries.
Uses
Used in Pharmaceutical Industry:
6-Chloro-2-iodo-3-hydroxypyridine is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, particularly those targeting neurological disorders or conditions that require modulation of specific receptors.
Used in Chemical Synthesis:
In the field of organic chemistry, 6-Chloro-2-iodo-3-hydroxypyridine serves as a valuable building block for the creation of more complex molecules. Its reactive sites, including the chlorine and iodine atoms, can be further functionalized to produce a wide range of chemical products with diverse applications.
Used in Research and Development:
Due to its unique structural features, 6-Chloro-2-iodo-3-hydroxypyridine is utilized in research and development laboratories for studying various chemical reactions and exploring new synthetic pathways. It can be employed as a model compound to understand the reactivity and behavior of similar molecules in different chemical environments.
Used in Material Science:
The compound may also find applications in the field of material science, where its unique properties can be harnessed to develop new materials with specific characteristics. For instance, it could be used to create novel polymers or coatings with enhanced properties, such as improved stability or resistance to certain conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 188057-26-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,8,0,5 and 7 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 188057-26:
(8*1)+(7*8)+(6*8)+(5*0)+(4*5)+(3*7)+(2*2)+(1*6)=163
163 % 10 = 3
So 188057-26-3 is a valid CAS Registry Number.
InChI:InChI=1/C5H3ClINO/c6-4-2-1-3(9)5(7)8-4/h1-2,9H
188057-26-3Relevant articles and documents
INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS
-
Page/Page column 40; 115, (2022/02/05)
Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.
CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF
-
Paragraph 00279; 00353, (2021/03/19)
The present disclosure describes compounds of the formula: (I), (II), (III), (IV), (V). The compounds described herein may be cyclooxygenase (COX) (e.g., cyclooxygenase 2 (COX2)) inhibitors. The compounds may be radiolabeled. The compounds (e.g., radiolabeled compounds) may be useful (e.g., as positron emission tomography (PET) imaging agents) for diagnosing a disease. The compounds may also be useful for treating or preventing a disease. The present disclosure also describes pharmaceutical compositions and kits including the compounds; and methods of using the compounds.
Structure-based design of tricyclic NF-κB inducing kinase (NIK) inhibitors that have high selectivity over phosphoinositide-3-kinase (PI3K)
Castanedo, Georgette M.,Blaquiere, Nicole,Beresini, Maureen,Bravo, Brandon,Brightbill, Hans,Chen, Jacob,Cui, Hai-Feng,Eigenbrot, Charles,Everett, Christine,Feng, Jianwen,Godemann, Robert,Gogol, Emily,Hymowitz, Sarah,Johnson, Adam,Kayagaki, Nobuhiko,Kohli, Pawan Bir,Knüppel, Kathleen,Kraemer, Joachim,Krüger, Susan,Loke, Pui,McEwan, Paul,Montalbetti, Christian,Roberts, David A.,Smith, Myron,Steinbacher, Stefan,Sujatha-Bhaskar, Swathi,Takahashi, Ryan,Wang, Xiaolu,Wu, Lawren C.,Zhang, Yamin,Staben, Steven T.
supporting information, p. 627 - 640 (2017/02/05)
We report here structure-guided optimization of a novel series of NF-κB inducing kinase (NIK) inhibitors. Starting from a modestly potent, low molecular weight lead, activity was improved by designing a type 11/2 binding mode that accessed a back pocket past the methionine-471 gatekeeper. Divergent binding modes in NIK and PI3K were exploited to dampen PI3K inhibition while maintaining NIK inhibition within these series. Potent compounds were discovered that selectively inhibit the nuclear translocation of NF-κB2 (p52/REL-B) but not canonical NF-κB1 (REL-A/p50).
